AstraZeneca ADR had its Relative Strength (RS) Rating upgraded from 67 to 72 Friday — a welcome improvement, but still shy of the 80 or better score you prefer to see.
This proprietary rating measures market leadership by using a 1 (worst) to 99 (best) score that shows how a stock's price action over the trailing 52 weeks compares to the rest of the market.
Over 100 years of market history reveals that the top-performing stocks tend to have an 80 or better RS Rating as they begin their biggest climbs. See if AstraZeneca ADR can continue to show renewed price strength and hit that benchmark.
How To Invest In Stocks In Both Bull And Bear Markets
AstraZeneca ADR is building a cup with handle with a 78.36 entry. See if the stock can clear the breakout price in heavy trade.
In terms of fundamentals, the company has posted rising EPS growth over the last two quarters. Top line growth has also moved higher over the same time frame.
AstraZeneca ADR earns the No. 1 rank among its peers in the Medical-Diversified industry group. Eli Lilly and Abbott Laboratories are also among the group's highest-rated stocks.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
